The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...

Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...

Nimble Therapeutics is a company that was spun out from Switzerland-based F. Hoffman-La Roche in 2019. It launched with the ...

US drugmaker AbbVie is to acquire Nimble Therapeutics, a USA-based Roche spinout developing oral peptide treatments in the ...

AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering ...

Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along ...

Nimble is backed by founding investors Telegraph Hill Partners and Roche Ventures. AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today ...

AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical ...